Platelets in tumor progression: A host factor that offers multiple potential targets in the treatment of cancer

Journal of Cellular Physiology

Volumn 229, Issue 8, 2014, Pages 1005-1015

  Sharma, Deva ^a   Brummel Ziedins, Kathleen E ^b   Bouchard, Beth A ^b   Holmes, Chris E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HOST FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; BLOOD VESSEL TONE; BONE DESTRUCTION; BONE METASTASIS; CANCER CELL; CANCER PREVENTION; CANCER PROGNOSIS; CANCER THERAPY; CELL MIGRATION; CIRCULATING TUMOR CELL; CYTOKINE PRODUCTION; DISTANT METASTASIS; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; MOLECULAR MIMICRY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PARACRINE SIGNALING; PLATELET MICROPARTICLE; PRIORITY JOURNAL; REVIEW; TARGET CELL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

BLOOD PLATELETS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; OSTEOCLASTS; PARACRINE COMMUNICATION;

EID: 84899072656     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24539     Document Type: Review

References (100)

1. Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW. 2004. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: Role of receptor glycoproteins. Br J Pharmacol 141:241-252.
2. Amirkhosravi A, Mousa SA, Amaya M, Blaydes S, Desai H, Meyer T, Francis JL. 2003. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 90:549-554.
3. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN. 2003. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 100:14205-14210.
4. Bambace NM, Holmes CE. 2011. The platelet contribution to cancer progression. J Thromb Haemost 9:237-249.
5. Bambace NM, Levis JE, Holmes CE. 2010. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 21:85-93.
6. Bando H, Yamashita T, Tsubura E. 1984. Effects of antiplatelet agents on pulmonary metastases. Gann 75:284-291.
7. Barry OP, Pratico D, Lawson JA, FitzGerald GA. 1997. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 99:2118-2127.
8. Barry OP, Pratico D, Savani RC, FitzGerald GA. 1998. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 102:136-144.
9. Bastida E, Escolar G, Almirall L, Ordinas A. 1986. Platelet activation induced by a human neuroblastoma tumor-cell line is reduced by prior administration of ticlopidine. Thromb Haemost 55:333-337.
10. Bastida E, Almirall L, Ordinas A. 1987. Tumor-cell-induced platelet-aggregation is a glycoprotein-dependent and lipoxygenase-associated process. Int J Cancer 39:760-763.
11. Battinelli EM, Markens BA, Italiano JE, Jr. 2011. Release of angiogenesis regulatory proteins from platelet alpha granules: Modulation of physiologic and pathologic angiogenesis. Blood 118:1359-1369.
12. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. 2001. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis (vol 98, pg 3352, 2001). Proc Natl Acad Sci USA 98:5369-5369.
13. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O. 2004. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114:1714-1725.
14. Boukerche H, Berthiervergnes O, Penin F, Tabone E, Lizard G, Bailly M, Mcgregor JL. 1994. Human-melanoma cell-lines differ in their capacity to release adp and aggregate platelets. Br J Haematol 87:763-772.
15. Bradley CJ, Dauer RJ, Thurlow PJ, Connellan JM. 1997. Characterization of platelet aggregation induced by the human carcinosarcoma Colo 526: Role of platelet activation, tumor cell cytoskeleton and tumor cell plasma membrane. Pathology 29:189-195.
16. Chatterjee M, Huang Z, Zhang W, Jiang L, Hultenby K, Zhu L, Hu H, Nilsson GP, Li N. 2011. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 117:3907-3911.
17. Chen HX, Cleck JN. 2009. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6:465-477.
18. Clezardin P. 2011. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 13:207-215.
19. Clohisy DR, Ramnaraine ML. 1998. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 16:660-666.
20. Cook KM, Figg WD. 2010. Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin 60:222-243.
21. Crissman JD, Hatfield J, Schaldenbrand M, Sloane BF, Honn KV. 1985. Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Lab Invest 53:470-478.
22. de Leval X, Benoit V, Delarge J, Julemont F, Masereel B, Pirotte B, Merville MP, David JL, Dogne M. 2003. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot Essent Fatty Acids 68:55-59.
23. Deryugina EI, Quigley JP. 2006. Matrix metalloproteinases and tumor metastasis. Cancer Metastatis Rev 25:9-34.
24. Erpenbeck L, Schon MP. 2010. Deadly allies: The fatal interplay between platelets and metastasizing cancer cells. Blood 115:3427-3436.
25. Feng W, Madajka M, Kerr BA, Mahabeleshwar GH, Whiteheart SW, Byzova TV. 2011. A novel role for platelet secretion in angiogenesis: Mediating bone marrow-derived cell mobilization and homing (vol 117, pg 3893, 2011). Blood 117:7187-7187.
26. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
27. Gay LJ, Felding-Habermann B. 2011. Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123-134.
28. Grignani G, Pacchiarini L, Ricetti MM, Dionigi P, Jemos V, Zucchella M, Fratino P. 1989. Mechanisms of platelet activation by cultured human cancer-cells and cells freshly isolated from tumor-tissues. Invasion Metastasis 9:298-309.
29. Grossi IM, Fitzgerald LA, Kendall A, Taylor JD, Sloane BF, Honn KV. 1987. Inhibition of human-tumor cell induced platelet-aggregation by antibodies to platelet glycoproteins Ib and Iib/Iiia. Proc Soc Exp Biol Med 186:378-383.
30. Gruber R, Karreth F, Fischer MB, Watzek G. 2002. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. Bone 30:726-732.
31. Guise TA, Mundy GR. 1998. Cancer and bone. Endocr Rev 19:18-54.
32. Hamilton J, Subbarao V, Granack K, Ts'ao C. 1986. Platelet interaction with a pancreatic ascites tumor. Am J Pathol 122:160-168.
33. Hoebertz A, Meghji S, Burnstock G, Arnett TR. 2001. Extracellular ADP is a powerful osteolytic agent: Evidence for signaling through the P2Y(1) receptor on bone cells. Faseb J 15:1139-1148.
34. Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. 2008. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clin Cancer Res 14:3070-3076.
35. Holmes CE, Jasielec J, Levis JE, Skelly J, Muss HB. 2013. Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Clin Transl Sci 6:386-390.
36. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. 2008. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 68:6851-6858.
37. Ho-Tin-Noe B, Goerge T, Wagner DD. 2009a. Platelets: Guardians of tumor vasculature. Cancer Res 69:5623-5626.
38. Ho-Tin-Noe B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. 2009b. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol 175:1699-1708.
39. Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. 2008. Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111:1227-1233.
40. Jain S, Russell S, Ware J. 2009. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 7:1713-1717.
41. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ. 2005. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113:752-760.
42. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. 2006. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 46:1199-1209.
43. Jelkmann W. 2001. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617-623.
44. Jones DS, Wallace AC, Fraser EE. 1971. Sequence of events in experimental metastases of Walker 256 tumor: Light, immunofluorescent, and electron microscopic observations. J Natl Cancer Inst 46:493-504.
45. Joyce JA, Pollard JW. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239-252.
46. Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I, Radomski MW. 2001a. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: Regulation by nitric oxide. Cancer Res 61:376-382.
47. Jurasz P, Stewart MW, Radomski A, Khadour F, Duszyk M, Radomski MW. 2001b. Role of von Willebrand factor in tumour cell-induced platelet aggregation: Differential regulation by NO and prostacyclin. Br J Pharmacol 134:1104-1112.
48. Jurasz P, Alonso-Escolano D, Radomski MW. 2004. Platelet-cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143:819-826.
49. Kerr BA, Miocinovic R, Smith AK, Klein EA, Byzova TV. 2010. Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model. Neoplasia 12:388-396.
50. Kim SJ, Choi IK, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. 2004. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: Correlations with clinical parameters and survival. Jpn J Clin Oncol 34:184-190.
51. Kopp HG, Placke T, Salih HR. 2009. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 69:7775-7783.
52. Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I. 2012. Cilengitide treatment for malignant glioma: Current status and future direction. Neurol Med Chir 52:539-547.
53. Kuznetsov HS, Marsh T, Markens BA, Castano Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS. 2012. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2:1150-1165.
54. Labelle M, Begum S, Hynes RO. 2011. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576-590.
55. Lal I, Dittus K, Holmes CE. 2013. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res 15:207.
56. Li X, Wu JF. 2010. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs). Recent Pat Anticancer Drug Discov 5:109-141.
57. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. 2000. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases-Long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082-1090.
58. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. 2005. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 102:216-220.
59. Malik AB. 1983. Pulmonary microembolism. Physiol Rev 63:1114-1207.
60. Mehta P, Lawson D, Ward MB, Leeambrose L, Kimura A. 1986. Effects of thromboxane A2 inhibition on osteogenic-sarcoma cell-induced platelet-aggregation. Cancer Res 46:5061-5063.
61. Mundy GR. 2002. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593.
62. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. 1993. Heparin oligosaccharides bind L-selectin and P-selectin and inhibit acute-inflammation. Blood 82:3253-3258.
63. Nieman MT, LaRusch G, Fang C, Zhou Y, Schmaier AH. 2010. Oral thrombostatin FM19 inhibits prostate cancer. Thromb Haemost 104:1044-1048.
64. Nierodzik ML, Klepfish A, Karpatkin S. 1994. Role of platelet integrin Gpiib-Gpiiia, fibronectin, Von-Willebrand-factor, and thrombin in platelet-tumor interaction in-vitro and metastasis in-vivo. Semin Hematol 31:278-288.
65. Nierodzik ML, Klepfish A, Karpatkin S. 1995. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 74:282-290.
66. Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, Kohsaka S. 2007. Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia 55:604-616.
67. Olas B, Mielicki WP, Wachowicz B, Krajewski T. 1999. Cancer procoagulant stimulates platelet adhesion. Thromb Res 94:199-203.
68. Oleksowicz L, Dutcher JP. 1995. Adhesive receptors expressed by tumor cells and platelets: Novel targets for therapeutic anti-metastatic strategies. Med Oncol 12:95-102.
69. Pacchiarini L, Zucchella M, Milanesi G, Tacconi F, Bonomi E, Canevari A, Grignani G. 1991. Thromboxane production by platelets during tumor cell-induced platelet activation. Invasion Metastasis 11:102-109.
70. Palumbo JS, Degen JL. 2007. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res 120:S22-S28.
71. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. 2005. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178-185.
72. Peterson JE, Zurakowski D, Italiano JE, Michel LV, Fox L, Klement GL, Folkman J. 2010. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 85:487-493.
73. Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, Baud L. 1993. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol 143:1713-1723.
74. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. 1998. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 125:1252-1257.
75. Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, Salih HR. 2012. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res 72:440-448.
76. Rosen LS. 2002. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol 29:28-32.
77. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B. 2002. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468.
78. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, Herbert JM. 2006. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 103:11069-11074.
79. Scheel C, Onder T, Karnoub A, Weinberg RA. 2007. Adaptation versus selection: The origins of metastatic behavior. Cancer Res 67:11476-11479.
80. Schreinemachers DM, Everson RB. 1994. Aspirin use and lung, colon, and breast-cancer incidence in a prospective-study. Epidemiology 5:138-146.
81. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, Chambers AF, Allan AL. 2008. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 112:243-254.
82. Shau H, Roth MD, Golub SH. 1993. Regulation of natural killer function by nonlymphoid cells. Nat Immun 12:235-249.
83. Sierko E, Wojtukiewicz MZ. 2007. Inhibition of platelet function: Does it offer a chance of better cancer progression control? Semin Thromb Hemost 33:712-721.
84. Sindelar WF, Tralka TS, Ketcham AS. 1975. Electron microscopic observations on formation of pulmonary metastases. J Surg Res 18:137-161.
85. Smyth SS, Tsakiris DA, Scudder LE, Coller BS. 2000. Structure and function of murine alpha IIb beta 3 (GPIIb/IIIa): Studies using monoclonal antibodies and beta 3-null mice. Thromb Haemost 84:1103-1108.
86. Stevenson JL, Varki A, Borsig L. 2007. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 120:S107-S111.
87. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J. Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. 2012. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610-618.
88. Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN. 2012. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest 122:3579-3592.
89. Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454.
90. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. 1993. Aspirin use and risk of fatal cancer. Cancer Res 53:1322-1327.
91. Timar J, Tovari J, Raso E, Meszaros L, Bereczky B, Lapis K. 2005. Platelet-mimicry of cancer cells: Epiphenomenon with clinical significance. Oncology 69:185-201.
92. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. 2002. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62:2824-2833.
93. Varki NM, Varki A. 2002. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: Rationale for clinical studies in humans. Semin Thromb Hemost 28:53-66.
94. Verheul HMW, Pinedo HM. 2007. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485.
95. Weilbaecher KN, Guise TA, McCauley LK. 2011. Cancer to bone: A fatal attraction. Nat Rev Cancer 11:411-425.
96. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. 2001. The hemostatic system and angiogenesis in malignancy. Neoplasia 3:371-384.
97. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. 2000. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979-2988.
98. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE, Ryeom S. 2010. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115:4605-4613.
99. Zitvogel L, Tesniere A, Kroemer G. 2006. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 6:715-727.
100. Zucchella M, Dezza L, Pacchiarini L, Meloni F, Tacconi F, Bonomi E, Grignani G, Notario A. 1989. Human tumor cells cultured "in vitro" activate platelet function by producing ADP or thrombin. Haematologica 74:541-545.